Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3

Interventions

Docetaxel 292Prednisone 241enzalutamide 195Leuprolide 185Radiotherapy 179Abiraterone Acetate 170Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 93abiraterone 83gallium 68 PSMA-11 81Specimen Handling 73darolutamide 67Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 53Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostatic Neoplasms × WW Domain-Containing Oxidoreductase × Genitourinary × Clear all
NCT04049747 2025-03-24

IP4-CHRONOS

Imperial College London

Phase NA Completed
100 enrolled 23 charts
Genitourinary

Prostatic Neoplasms

NCT04239599 2022-09-29

RCT-PHART2

Sunnybrook Health Sciences Centre

Phase NA Unknown
178 enrolled
Genitourinary

Prostatic Neoplasms

NCT00064610 2008-02-11

Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer

Millennium Pharmaceuticals, Inc.

Phase 1/2 Completed
102 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡